Semax + Selank

Semax + Selank is a vendor blend that pairs two distinct research peptides. Semax is a peptide derived from a fragment of ACTH (roughly the ACTH(4-10) region) that has been studied as a nootropic, meaning research interest has focused on cognition and neuroprotection. Selank is a synthetic analog of the immunopeptide tuftsin that has been studied as an anxiolytic, meaning research interest has focused on anxiety-related endpoints.

Both peptides were developed in Russia, where they have seen clinical use, but neither is FDA-approved in the United States. Importantly, there are no dedicated trials of this specific combination; anything said about the blend is extrapolated from studies of each component individually.

Because this is a blend, its proposed mechanisms are simply those of its two parts, considered together:

• Semax — studied for hypothesized effects on brain-derived neurotrophic factor (BDNF) and related neurotrophic and neuromodulatory pathways.
• Selank — studied for hypothesized effects on GABAergic and serotonergic tone and on regulatory immune peptides, consistent with its tuftsin-analog origin.

The reasoning behind pairing them is that a cognition-oriented peptide and an anxiety-oriented peptide might be complementary. That rationale is conceptual; there is no controlled evidence that combining them produces additive or synergistic effects in humans.

In Russia, Semax and Selank have been used clinically for their respective neurological and anxiety-related indications. In the United States and many other jurisdictions, neither is an approved medicine, and the combination has no recognized medical indication at all.

Where the blend appears, it is generally in an experimental or wellness-oriented context. Any consideration of it should be grounded in local regulations and in the recognition that combining two unapproved peptides compounds, rather than reduces, the surrounding uncertainty.

Athletes subject to anti-doping rules should treat any unapproved research peptide cautiously and consult their governing body, since catch-all provisions may apply even when a compound is not named explicitly.

Reported experiences with the individual peptides tend to be described as mild, but robust, long-term safety data across diverse populations are limited. Combining two agents also introduces the general possibility of overlapping or unpredictable effects that single-agent studies cannot capture.

As with other experimental peptides, careful attention to product sourcing, regulatory guidance, and individual risk factors is important. High-level summaries cannot substitute for rigorous safety evaluation, which for this combination has not been done.

Semax and Selank are short peptides that are often discussed in intranasal as well as injectable forms, and short peptides are generally thought to be rapidly metabolized. Detailed, well-characterized human pharmacokinetics for the combined product are not established.

Any real-world decisions, if made at all, belong within controlled research under expert supervision rather than self-directed use.

The two halves of this blend came out of the same Russian research programme but are chemically and pharmacologically unrelated:

• Semax — an analogue of the ACTH(4-10) fragment with a proline-glycine-proline tail added to resist enzymatic breakdown. Studied for neuroprotection and post-stroke recovery, typically administered intranasally in the Russian trials.

• Selank — a synthetic analogue of the immunopeptide tuftsin, studied for anxiety and evaluated against benzodiazepine comparators rather than placebo.

Both are registered medicines in Russia and neither is FDA- or EMA-approved. Both also appear on the FDA's list of bulk drug substances that may present significant safety risks in compounding — for Semax the agency states it "has no, or limited, safety-related information for proposed routes of administration," and for selank acetate that it "lacks important information regarding any safety issues raised by selank acetate administered to humans" (FDA bulk drug substances page). Both nominations were later withdrawn by the parties that submitted them.

Nothing about being sold in one vial changes either component's status, and no standardised ratio between them exists in any pharmacopoeia or published protocol.

The research picture for this entry is really two separate literatures. Semax has been studied for cognitive and neuroprotective endpoints, and Selank for anxiety-related endpoints, largely in Russian clinical and preclinical work. Independent replication outside Russia is limited for both.

Critically, the combination itself has not been studied in dedicated trials, so any claim about the blend is an extrapolation. Statements should be framed as hypothesized, and the leap from two single-agent literatures to a combined product should be made explicit rather than glossed over.

For deeper dives on this blend and its components, see:

• Semax + Selank benefits and areas of interest
• Semax + Selank side effects and safety context
• Semax + Selank dosing concepts (educational)
• Semax + Selank research and evidence overview
• Semax (component) overview
• Selank (component) overview

Has this combination ever been studied? No — and the closest study deliberately kept them apart. A resting-state fMRI experiment in 52 healthy participants gave each person Semax, or Selank, or placebo, and analysed the two peptides' effects on amygdala connectivity separately (Panikratova et al., Dokl Biol Sci 2020). Neither that study nor any other has given both peptides together. Everything said about the blend is an inference from two unconnected literatures.

What human evidence exists for each component? A small amount, all from Russia and all with active comparators rather than placebo. The foundational Selank study compared it with the benzodiazepine medazepam in 62 patients with generalized anxiety disorder and neurasthenia, reporting similar anxiolytic effects plus antiasthenic and psychostimulant effects (Zozulia et al. 2008). For Semax, 110 patients recovering from ischemic stroke received two 10-day courses at 6,000 mcg/day; plasma BDNF rose and Barthel index recovery was faster (Gusev et al. 2018). Neither population resembles a healthy adult taking a blend.

Are Semax and Selank approved anywhere? Both are registered medicines in Russia. Neither has FDA or EMA authorisation, neither has any ClinicalTrials.gov registration, and the blend has no approved status anywhere. A national registration reflects that regulator's evidentiary standard — in this case one that accepted trials which were not blinded or placebo-controlled.

Is what is sold actually Semax and Selank? Sometimes it is — which is itself the finding. A Belgian official medicines control laboratory analysed two suspicious unlabelled preparations seized in 2017 and 2018 and identified Selank and Semax in them, noting these peptides "have not completed any clinical trials," and went on to build an LC-MS/MS screen covering ten such peptides sold online (Vanhee et al., Drug Test Anal 2020). Forensic identification of a compound in a seized vial is not the same as a purity, potency, or sterility specification for a product someone buys.

Why pair a nootropic with an anxiolytic? The rationale is conceptual symmetry — one peptide studied for cognition, one for anxiety — not a finding. No study has tested whether the two interact favourably, neutrally, or unfavourably, whether one blunts the other, or whether a fixed ratio suits anyone. A fixed combination also removes the ability to change one component without changing both.

Does the blend match how these peptides were actually given? Not necessarily. The Russian human work used defined intranasal courses — for example two 10-day Semax courses separated by a 20-day interval (Gusev 2018) — rather than continuous combined dosing. A vendor blend is a different product, a different schedule, and often a different route from the studies it borrows credibility from.